Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

Krazati has been cleared as a treatment for patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) after one prior systemic therapy – the same indication given to Amgen's Lumakras ...

Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

Amgen is running a confirmatory phase 3 trial called CodeBreak 200 that is comparing Lumakras to the chemotherapy agent docetaxel in previously-treated patients with KRAS G12C-mutated NSCLC ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...